Scott T Tagawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8511197/publications.pdf

Version: 2024-02-01

206	13,899	61857 43	22764 112
papers	citations	h-index	g-index

215	215	215	14788
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
2	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	15.2	1,193
3	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 385, 1091-1103.	13.9	1,042
4	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2019, 381, 338-348.	13.9	885
5	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	7.7	725
6	Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. Cancer Research, 2011, 71, 6019-6029.	0.4	400
7	Phase II Study of Lutetium-177â€“Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191.	3.2	370
8	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	0.8	267
9	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	3.4	264
10	Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature Genetics, 2016, 48, 1490-1499.	9.4	250
11	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of Clinical Oncology, 2021, 39, 2474-2485.	0.8	250
12	Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404.	5.8	246
13	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer. Neoplasia, 2013, 15, 1-IN4.	2.3	205
14	Clinical features of neuroendocrine prostate cancer. European Journal of Cancer, 2019, 121, 7-18.	1.3	195
15	Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer. Journal of Clinical Oncology, 2012, 30, e386-e389.	0.8	185
16	Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device. PLoS ONE, 2012, 7, e35976.	1.1	185
17	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	3.2	177
18	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	3.2	163

#	Article	IF	Citations
19	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treatment Reviews, 2017, 57, 16-27.	3.4	156
20	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
21	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature Communications, 2019, 10, 2977.	5.8	140
22	CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	1.5	138
23	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. Journal of Clinical Oncology, 2018, 36, 3251-3258.	0.8	129
24	Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood, 2019, 133, 781-789.	0.6	127
25	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Journal of Clinical Investigation, 2020, 130, 1653-1668.	3.9	122
26	Antiâ€“prostateâ€specific membrane antigenâ€based radioimmunotherapy for prostate cancer. Cancer, 2010, 116, 1075-1083.	2.0	120
27	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2016, 22, 1510-1519.	3.2	117
28	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	105
29	Phase 1/2 study of fractionated dose lutetiumâ€177â€“labeled antiâ€“prostateâ€specific membrane antigen monoclonal antibody J591 (¹⁷⁷Luâ€J591) for metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 2561-2569.	2.0	100
30	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology, 2018, 73, 687-693.	0.9	99
31	ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications, 2014, 5, 5548.	5.8	96
32	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical Cancer Research, 2019, 25, 1880-1888.	3.2	92
33	Doubleâ€blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 692-701.	2.0	91
34	PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Seminars in Nuclear Medicine, 2011, 41, 29-44.	2.5	84
35	Sacituzumab Govitecan, a Novel Antibodyâ€“Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e75-e79.	0.9	80
36	Prostate-Specific Membrane Antigen-Based Therapeutics. Advances in Urology, 2012, 2012, 1-9.	0.6	74

#	Article	IF	Citations
37	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-NaÂ¯ve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	0.8	73
38	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 1500-1509.	0.8	72
39	Randomized phase <scp>II</scp> study of danusertib in patients with metastatic castrationâ€resistant prostate cancer after docetaxel failure. BJU International, 2013, 111, 44-52.	1.3	67
40	Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.. Journal of Clinical Oncology, 2019, 37, 354-354.	0.8	67
41	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA;) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 FGFR alterations (FGFRalt).. Journal of Clinical Oncology, 2018, 36, 4503-4503.	0.8	63
42	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
43	PSMA ADC monotherapy in patients with progressive metastatic castrationâ€resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in openâ€label singleâ€arm phase 2 study. Prostate, 2020, 80, 99-108.	1.2	45
44	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature Communications, 2021, 12, 3372.	5.8	45
45	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1157-1164.	1.9	44
46	Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. Journal of Clinical Oncology, 2020, 38, 1736-1743.	0.8	44
47	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1285-1301.	1.5	42
48	Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow. PLoS ONE, 2013, 8, e85143.	1.1	40
49	Meeting report from the Prostate Cancer Foundation PSMAâ€directed radionuclide scientific working group. Prostate, 2018, 78, 775-789.	1.2	35
50	Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2013, 3, 214.	1.3	33
51	Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. Annals of Neurology, 2021, 90, 159-169.	2.8	31
52	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precision Oncology, 2017, 2017, 1-13.	1.5	30
53	Neuroendocrine Prostate Cancer After Hormonal Therapy: Knowing Is Half the Battle. Journal of Clinical Oncology, 2014, 32, 3360-3364.	0.8	29
54	Antibody-Drug Conjugates in Bladder Cancer. Bladder Cancer, 2018, 4, 247-259.	0.2	29

#	Article	IF	Citations
55	Phase I trial of docetaxel plus lutetium-177-labeled antiâ€“prostateâ€specific membrane antigen monoclonal antibody J591 (177Luâ€J591) for metastatic castrationâ€resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e9-848.e16.	0.8	29
56	Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer and Prostatic Diseases, 2021, 24, 1032-1040.	2.0	28
57	A phase I/II study of rovalpituzumab tesirine in delta-like 3â€"expressing advanced solid tumors. Npj Precision Oncology, 2021, 5, 74.	2.3	27
58	Pilot Study of Hyperfractionated Dosing of Lutetium-177â€"Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2020, 25, 477-e895.	1.9	26
59	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651.	3.3	26
60	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 630589.	1.3	26
61	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	0.8	26
62	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.. Journal of Clinical Oncology, 2022, 40, 434-434.	0.8	26
63	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	24
64	Phase I study of ²²⁵Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5015-5015.	0.8	24
65	Treatment patterns and survival in metastatic castrationâ€sensitive prostate cancer in the US Veterans Health Administration. Cancer Medicine, 2021, 10, 8570-8580.	1.3	22
66	Common germline-somatic variant interactions in advanced urothelial cancer. Nature Communications, 2020, 11, 6195.	5.8	21
67	Phase I dose-escalation study of ²²⁵Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, TPS399-TPS399.	0.8	20
68	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. Journal of Clinical Oncology, 2020, 38, 5015-5015.	0.8	17
69	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5543-5543.	0.8	17
70	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 114-114.	0.8	17
71	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
72	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	2.0	15

#	Article	IF	Citations
73	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. Journal of Clinical Oncology, 2020, 38, 15-15.	0.8	15
74	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British Journal of Cancer, 2022, 126, 430-439.	2.9	15
75	Use of Biosimilar Medications in Oncology. JCO Oncology Practice, 2022, 18, 177-186.	1.4	15
76	BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.. Journal of Clinical Oncology, 2022, 40, 5018-5018.	0.8	15
77	Imaging expression of prostateâ€specific membrane antigen and response to PSMAâ€targeted Î²â€emitting radionuclide therapies in metastatic castrationâ€resistant prostate cancer. Prostate, 2021, 81, 279-285.	1.2	14
78	Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. European Urology Focus, 2021, 7, 254-257.	1.6	14
79	Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.. Journal of Clinical Oncology, 2020, 38, 5027-5027.	0.8	14
80	Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Physical Biology, 2019, 16, 036003.	0.8	13
81	Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 450-450.	0.8	13
82	CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy, 2020, 28, 1238-1250.	3.7	12
83	A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).. Journal of Clinical Oncology, 2015, 33, 144-144.	0.8	12
84	Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU International, 2008, 102, 1086-1091.	1.3	11
85	Validation of a Circulating Tumor <scp>DNA</scp>-Based <scp>Next-Generation</scp> Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist, 2021, 26, e1971-e1981.	1.9	11
86	Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 511-511.	0.8	11
87	Immunologics and Chemotherapeutics for Renal Cell Carcinoma. Seminars in Interventional Radiology, 2014, 31, 091-097.	0.3	10
88	Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. Stroke, 2019, 50, 3259-3264.	1.0	10
89	NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1383-1389.	1.2	10
90	Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis. Advances in Urology, 2010, 2010, 1-3.	0.6	9

#	Article	IF	Citations
91	A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 443-448.	0.6	9
92	Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Current Oncology Reports, 2021, 23, 59.	1.8	9
93	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5560-5560.	0.8	9
94	Outcomes of preoperative chemotherapy in bladder cancer patients including node-positive disease.. Journal of Clinical Oncology, 2015, 33, 370-370.	0.8	9
95	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	8
96	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. Journal of Clinical Oncology, 2019, 37, 272-272.	0.8	8
97	Pilot study of the diagnostic utility of 89 Zrâ€dfâ€IAB2M and 68 Gaâ€PSMAâ€11 PET imaging and multiparametric MRI in localized prostate cancer. Prostate, 2022, , .	1.2	8
98	Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. Journal of Thrombosis and Haemostasis, 2022, 20, 2046-2057.	1.9	8
99	Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 4529-4529.	0.8	8
100	An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 863-870.	0.9	7
101	Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody ¹⁷⁷lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5064-5064.	0.8	7
102	Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2015, 33, 295-295.	0.8	7
103	Final results of 2-dose fractionation of ¹⁷⁷Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5022-5022.	0.8	6
104	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	6
105	What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. European Urology Open Science, 2022, 40, 58-94.	0.2	6
106	The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer. Prostate Cancer, 2012, 2012, 1-8.	0.4	5
107	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. Expert Opinion on Biological Therapy, 2017, 17, 135-149.	1.4	5
108	A critical review on ramucirumab in the treatment of advanced urothelial cancer. Future Oncology, 2018, 14, 1049-1061.	1.1	5

#	Article	IF	Citations
109	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.. Journal of Clinical Oncology, 2021, 39, 41-41.	0.8	5
110	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using ¹⁷⁷Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. Journal of Clinical Oncology, 2021, 39, TPS5087-TPS5087.	0.8	5
111	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2013, 31, TPS5096-TPS5096.	0.8	5
112	Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 204-204.	0.8	5
113	Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2014, 32, 177-177.	0.8	5
114	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular Oncology, 2022, 16, 2384-2395.	2.1	5
115	Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.. Journal of Clinical Oncology, 2021, 39, 5042-5042.	0.8	4
116	TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, TPS5100-TPS5100.	0.8	4
117	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. Journal of Clinical Oncology, 2015, 33, 197-197.	0.8	4
118	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5007-5007.	0.8	4
119	Archexin, a novel AKT-1â€“specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.. Journal of Clinical Oncology, 2016, 34, 550-550.	0.8	4
120	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3552-3552.	0.8	4
121	Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.. Journal of Clinical Oncology, 2020, 38, TPS5092-TPS5092.	0.8	4
122	TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naÃ¯ve patients (pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2022, 40, TPS581-TPS581.	0.8	4
123	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	1.6	4
124	PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert Opinion on Therapeutic Patents, 2013, 23, 665-668.	2.4	3
125	Trimodality therapy in variant urothelial carcinoma: choose wisely. Translational Andrology and Urology, 2017, 6, 322-325.	0.6	3
126	Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. Journal of Oncology Practice, 2019, 15, 343-345.	2.5	3

#	Article	IF	Citations
127	Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. Journal of Urology, 2021, 205, 554-560.	0.2	3
128	Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.. Journal of Clinical Oncology, 2021, 39, 46-46.	0.8	3
129	Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress. Clinical Cancer Research, 2021, 27, PO-077-PO-077.	3.2	3
130	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications Biology, 2021, 4, 785.	2.0	3
131	Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. JAMA Oncology, 2021, 7, 1642.	3.4	3
132	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 447-456.	0.9	3
133	Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy.. Journal of Clinical Oncology, 2012, 30, 100-100.	0.8	3
134	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. Journal of Clinical Oncology, 2012, 30, 173-173.	0.8	3
135	Noninvasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: A prognostic tool for metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 11081-11081.	0.8	3
136	Association of CTCAE v4 grading of hypertension with toxicity in patients with renal cancer receiving vascular endothelial growth factor (VEGF)-targeting agents.. Journal of Clinical Oncology, 2013, 31, 447-447.	0.8	3
137	Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.. Journal of Clinical Oncology, 2014, 32, 25-25.	0.8	3
138	Defining a molecular subclass of treatment resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5004-5004.	0.8	3
139	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. Journal of Clinical Oncology, 2016, 34, 354-354.	0.8	3
140	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2019, 37, TPS495-TPS495.	0.8	3
141	Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, TPS5590-TPS5590.	0.8	3
142	Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2011, 13, 785-786.	0.8	3
143	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science, 2021, 34, 70-78.	0.2	3
144	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	5.8	3

#	Article	IF	Citations
145	A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).. Journal of Clinical Oncology, 2022, 40, 5082-5082.	0.8	3
146	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS188-TPS188.	0.8	2
147	D-Dimer Levels Among Cancer Patients with Unsuspected Pulmonary Embolism: Clinical Correlates and Relevance. Blood, 2012, 120, 1154-1154.	0.6	2
148	Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5025-5025.	0.8	2
149	Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 194-194.	0.8	2
150	Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma.. Journal of Clinical Oncology, 2016, 34, 2559-2559.	0.8	2
151	Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. Journal of Clinical Oncology, 2020, 38, 3055-3055.	0.8	2
152	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS216-TPS216.	0.8	2
153	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. Journal of Clinical Oncology, 2021, 39, 120-120.	0.8	1
154	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 158-158.	0.8	1
155	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 569-576.	0.8	1
156	Tinzaparin Is Effective and Safe for the Treatment and Extended Secondary Prophylaxis In Cancer Patients with Venous Thromboembolism.. Blood, 2010, 116, 1104-1104.	0.6	1
157	Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.. Journal of Clinical Oncology, 2013, 31, 121-121.	0.8	1
158	Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 205-205.	0.8	1
159	Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, 4513-4513.	0.8	1
160	Upper tract urothelial carcinoma is non-basal and T-cell depleted.. Journal of Clinical Oncology, 2018, 36, 4525-4525.	0.8	1
161	Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).. Journal of Clinical Oncology, 2019, 37, 5013-5013.	0.8	1
162	Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.. Journal of Clinical Oncology, 2013, 31, e15600-e15600.	0.8	1

#	Article	IF	Citations
163	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 158-158.	0.8	1
164	Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.. Journal of Clinical Oncology, 2015, 33, 5031-5031.	0.8	1
165	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. Journal of Clinical Oncology, 2019, 37, TPS348-TPS348.	0.8	1
166	Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17503-e17503.	0.8	1
167	Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 45-45.	0.8	1
168	Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106297.	0.7	1
169	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of ²²⁵Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 77-77.	0.8	1
170	Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer.. Journal of Clinical Oncology, 2022, 40, 96-96.	0.8	1
171	Phase I/II study of ²²⁵Ac-J591 plus ¹⁷⁷Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS5100-TPS5100.	0.8	1
172	Tolerability of [¹⁷⁷Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.. Journal of Clinical Oncology, 2022, 40, 5047-5047.	0.8	1
173	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 140-140.	0.8	0
174	Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2021, 39, 90-90.	0.8	0
175	Abstract P745: Whole Blood MicroRNA and Their Target Messenger RNA Reveal Distinct Transcriptional Changes in Ischemic Stroke Patients With and Without Comorbid Cancer. Stroke, 2021, 52, .	1.0	0
176	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. Journal of Clinical Oncology, 2021, 39, TPS5095-TPS5095.	0.8	0
177	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. Journal of Clinical Oncology, 2021, 39, TPS5091-TPS5091.	0.8	0
178	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. Journal of Clinical Oncology, 2021, 39, 5055-5055.	0.8	0
179	Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. Journal of Vascular and Interventional Radiology, 2021, 32, 1243-1244.	0.2	0
180	Reply to T. Powles et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01673.	0.8	0

#	Article	IF	Citations
181	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 528-547.	0.8	0
182	Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics.. Journal of Clinical Oncology, 2012, 30, 190-190.	0.8	0
183	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2012, 30, 120-120.	0.8	0
184	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. Journal of Clinical Oncology, 2012, 30, 110-110.	0.8	0
185	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. Journal of Clinical Oncology, 2012, 30, 4649-4649.	0.8	0
186	Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, 290-290.	0.8	0
187	Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.. Journal of Clinical Oncology, 2015, 33, 164-164.	0.8	0
188	Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count.. Journal of Clinical Oncology, 2015, 33, 199-199.	0.8	0
189	Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.. Journal of Clinical Oncology, 2015, 33, 5054-5054.	0.8	0
190	Use and outcomes of metastasectomy in older patients with urothelial cancers.. Journal of Clinical Oncology, 2015, 33, e15506-e15506.	0.8	0
191	Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2016, 34, 379-379.	0.8	0
192	Fractionated dose radiolabeled antiâ^'prostate specific membrane antigen (PSMA) radioimmunotherapy (177Luâ^'J591) for progressive metastatic castrationâ^'resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 205-205.	0.8	0
193	Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 268-268.	0.8	0
194	Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. Journal of Clinical Oncology, 2018, 36, 172-172.	0.8	0
195	Nadir testosterone (T) following in-situ polymer delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. Journal of Clinical Oncology, 2018, 36, 204-204.	0.8	0
196	Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, e17039-e17039.	0.8	0
197	Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies.. Journal of Clinical Oncology, 2020, 38, 12090-12090.	0.8	0
198	Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS5096-TPS5096.	0.8	0

#	Article	IF	Citations
199	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. Journal of Clinical Oncology, 2020, 38, TPS5594-TPS5594.	0.8	0
200	Overall survival (OS) in men with chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).. Journal of Clinical Oncology, 2020, 38, 40-40.	0.8	0
201	Abstract WP198: Hematological And Embolic Biomarkers And Clinical Outcomes In Patients With Cancer And Ischemic Stroke. Stroke, 2022, 53, .	1.0	0
202	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 532-532.	0.8	0
203	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. Journal of Clinical Oncology, 2022, 40, 139-139.	0.8	0
204	BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotypeâ€"Phase 2a interim results.. Journal of Clinical Oncology, 2022, 40, 126-126.	0.8	0
205	Quantitative assessment of PSMA imaging before and after ¹⁷⁷Lu-PSMA-617 treatment in a Ph I/II trial.. Journal of Clinical Oncology, 2022, 40, 37-37.	0.8	0
206	Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.. Journal of Clinical Oncology, 2022, 40, e17007-e17007.	0.8	0